Paul Tudor Jones’s Teva Pharmaceuticals TEVA Stock Holding History

Paul Tudor Jones’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$945K	Sell	27,900 -99,000	-78%	-$3.3M	﹤0.01%	2458
2026 Q1	$3.82M	Sell	126,900 -168,200	-57%	-$5.41M	0.01%	1350
2025 Q4	$9.21M	Buy	295,100 +280,600	+1,935%	+$6.91M	0.02%	793
2025 Q3	$293K	Sell	14,500 -67,300	-82%	-$1.18M	﹤0.01%	2992
2025 Q2	$1.37M	Buy	81,800 +33,400	+69%	+$539K	﹤0.01%	1929
2025 Q1	$744K	Buy	48,400 +13,500	+39%	+$241K	﹤0.01%	2022
2024 Q4	$769K	Sell	34,900 -26,500	-43%	-$482K	﹤0.01%	1914
2024 Q3	$1.11M	Buy	61,400 +46,000	+299%	+$805K	﹤0.01%	1552
2024 Q2	$250K	Buy	+15,400	New	+$237K	﹤0.01%	2077

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Paul Tudor Jones's TEVA Position: Q2 2026 in Review

Paul Tudor Jones reduced its Teva Pharmaceuticals (TEVA) stake by 10% in Q2 2026, selling an estimated $1.82M and leaving 490,000 shares worth $16.6M. The position accounts for 0.02% of the portfolio, ranked #572.

Paul Tudor Jones first reported a position in TEVA in Q1 2014 and has held it in 28 quarters since. The position peaked at $34.3M in Q1 2015. 671 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Paul Tudor Jones held 490,000 shares of Teva Pharmaceuticals worth $16.6M as of Q2 2026.
Paul Tudor Jones sold 54,501 Teva Pharmaceuticals shares in Q2 2026, an estimated $1.82M.
Teva Pharmaceuticals made up 0.02% of Paul Tudor Jones's portfolio in Q2 2026, its #572 holding.
Paul Tudor Jones first reported a position in Teva Pharmaceuticals in Q1 2014 and has held it in 28 quarters since.
Paul Tudor Jones's Teva Pharmaceuticals position peaked at $34.3M in Q1 2015.
671 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.